Swiss National Bank
BCAX

Swiss National Bank’s Bicara Therapeutics BCAX Stock Holding History

Swiss National Bank’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
59,200
+4,200
+8% +$93.7K ﹤0.01% 2003
2026
Q1 		$1.09M Buy
55,000
+22,700
+70% +$391K ﹤0.01% 2119
2025
Q4 		$544K Buy
+32,300
New +$552K ﹤0.01% 2280

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Swiss National Bank's BCAX Position: Q2 2026 in Review

Swiss National Bank increased its Bicara Therapeutics (BCAX) stake by 7.6% in Q2 2026, buying an estimated $93.7K and bringing the position to 59,200 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2003.

Swiss National Bank first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Swiss National Bank held 59,200 shares of Bicara Therapeutics worth $1.76M as of Q2 2026.
  • Swiss National Bank bought 4,200 Bicara Therapeutics shares in Q2 2026, an estimated $93.7K.
  • Bicara Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2003 holding.
  • Swiss National Bank first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.